
Appendix 17c: Forest plots for clinical evidence reviews on psychological vs. pharmacological interventions, combination therapy and other medical interventions

Psychological vs. Pharmacological (OCD) Combination therapy (OCD) Other medical interventions

Psychological vs. Pharmacological (OCD)

Review: OCD: psychological v pharmacological Comparison: 01 ERP vs Clomipramine

Outcome: 01 Y-BOCS or Compulsion checklist




Review: OCD: psychological v pharmacological

Comparison: 01 ERP vs Clomipramine
Outcome: 02 Leaving the study early

Study or sub-category	ERP n/N	Clomipramine n/N	RR (fixed) 95% CI	RR (fixed) 95% Cl
Foa 2005	16/37	20/47	-	1.02 [0.62, 1.67]
Total (95% CI) Total events: 16 (ERP), 20 (0 Test for heterogeneity: not a Test for overall effect: Z = 0	applicable	47	+	1.02 [0.62, 1.67]
		0.1	0.2 0.5 1 2 5	10
			Favours ERP Favours Clomi	pramine

Review: OCD: psychological v pharmacological

Comparison: 01 ERP vs Clomipramine Outcome: 03 Non-responders (CGI)



OCD: psychological v pharmacological Review: 02 Children: CBT v Clomipramine Comparison: Outcome: 01 Leaving the study early

Study or sub-category	CBT n/N	Clomipramine n/N	RR (fixed) 95% Cl	RR (fixed) 95% CI
de Haan 1998	1/13	0/10		- 2.36 [0.11, 52.41]
Total (95% CI) Test for heterogeneity: not applicable Test for overall effect: Z = 0.54 (P = 0.5	1/13 9)	0/10		- 2.36 [0.11, 52.41]
		0.01	0.1 1 10	100

Favours CBT Favours Clomipramine

Favours CBT Favours Clomipramine

Favours CBT Favours Clomipramine

Review: OCD: psychological v pharmacological 02 Children: CBT v Clomipramine Comparison:

02 Non-responders (CY-BOCS 30%) Outcome:

Study or sub-category	CBT n/N	Clomipramine n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
de Haan 1998	5/13	5/10		0.77 [0.30, 1.94]
Total (95% CI) Test for heterogeneity: not applicable Test for overall effect: Z = 0.56 (P = 0.5	5/13 8)	5/10		0.77 [0.30, 1.94]
			0.1 0.2 0.5 1 2	5 10
			Favours CBT Favours Clo	mipramine

OCD: psychological v pharmacological 02 Children: CBT v Clomipramine 03 CY-BOCS Review: Comparison:

Outcome:

Study or sub-category	N	CBT Mean (SD)	N	Clomipramine Mean (SD)		SMD (fix 95% C	•	SMD (fixed) 95% Cl
de Haan 1998	12	9.10(9.10)	10	17.60(11.80)		-		-0.79 [-1.66, 0.09]
Total (95% CI) Test for heterogeneity: no Test for overall effect: Z =			10			-		-0.79 [-1.66, 0.09]
Test for overall effect. Z =	1.76 (P = 0.06)				-4	-2 0		4

OCD: psychological v pharmacological 02 Children: CBT v Clomipramine Review: Comparison: Outcome: 04 Leyton Inventory - child version

Study or sub-category	N	CBT Mean (SD)	N	Clomipramine Mean (SD)		SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
de Haan 1998	12	12.70(9.30)	10	17.50(10.50)		-	-0.47 [-1.32, 0.38]
Total (95% CI) Test for heterogeneity: not Test for overall effect: Z =			10			-	-0.47 [-1.32, 0.38]
					-4	-2 0	 1

OCD: psychological v pharmacological 02 Children: CBT v Clomipramine 05 Child Behaviour Checklist Review: Comparison:

Study or sub-category	N	CBT Mean (SD)	N	Clomipramine Mean (SD)		SMD (fixed 95% CI)		SMD (fixed) 95% Cl
de Haan 1998	11	57.60(12.60)	8	60.50(9.30)		-			-0.24 [-1.16, 0.67]
Total (95% CI) Test for heterogeneity: not Test for overall effect: Z =	• •		8			-			-0.24 [-1.16, 0.67]
					-4	-2 0 Favours CBT Fav	2 Yours Clomin	4	

OCD: psychological v pharmacological 02 Children: CBT v Clomipramine Review: Comparison: 06 Children's Depression Inventory Outcome:

Study or sub-category	N	CBT Mean (SD)	N	Clomipramine Mean (SD)			ID (fixed) 95% CI			SMD (fixed) 95% Cl	
de Haan 1998	11	129.20(50.80)	9	143.20(37.90)					-0	.29 [-1.18, 0.59]	
Total (95% CI) Test for heterogeneity: not ag Test for overall effect: Z = 0.0			9			-			-0	.29 [-1.18, 0.59]	
					-4	-2	ó	2	4		

Favours CBT Favours Clomipramine

Favours CBT Favours Sertraline

Review: OCD: psychological v pharmacological

03 Children: CBT v Sertraline Comparison: Outcome: 01 Leaving the study early

RR (fixed) 95% Cl Sertraline CBT RR (fixed) Study n/N n/N 95% CI or sub-category POTS 2004 1.50 [0.27, 8.30] 3/28 2/28 Total (95% CI) 3/28 2/28 1.50 [0.27, 8.30] Test for heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64) 0.1 0.2 0.5 10


Review: OCD: psychological v pharmacological

Comparison: Outcome: 03 Children: CBT v Sertraline 02 CY-BOCS

Study or sub-category	N	CBT Mean (SD)	N	Sertraline Mean (SD)			D (fixed 95% CI	t)		SMD (fixed) 95% CI
POTS 2004	28	14.00(9.50)	28	16.50(9.10)	_	-		-		-0.27 [-0.79, 0.26]
Total (95% CI) Test for heterogeneity: no Test for overall effect: Z =			28		- -			-		-0.27 [-0.79, 0.26]
					-1	-0.5	Ó	0.5	1	
					1	Favours CB1	T Fav	vours Sertra	aline	

Combination therapy (OCD)

Review: OCD: combination therapy 01 ERP+ SRI v ERP Comparison: Outcome: 01 Leaving the study early



Review: OCD: combination therapy Comparison: 01 ERP+ SRI v ERP

Outcome:


02 Leaving the study early due to adverse effects

Study or sub-category	ERP+ SRI n/N	ERP n/N	RR (fixed 95% CI))	RR (fixed) 95% Cl
01 ERP + Fluvoxamine v ERP + p	olacebo				
Cottraux 1990	2/20	1/20			2.00 [0.20, 20.33]
Subtotal (95% CI)	2/20	1/20			2.00 [0.20, 20.33]
Test for heterogeneity: not appli-	cable				•
Test for overall effect: Z = 0.59	(P = 0.56)				
			0.01 0.1 1	10 1	· 00
			Favours ERP+SRI Fa	vours ERP	

OCD: combination therapy Review:

Comparison: 01 ERP+ SRI v ERP

03 Non-responders (Y-BOCS 35%) Outcome:



Review: OCD: combination therapy Comparison: 01 ERP+ SRI v ERP 04 Non-responders (CGI) Outcome:

Study or sub-category	ERP + SRI n/N	ERP n/N		RR (fixed) 95% Cl		RR (fixed) 95% Cl
01 ERP + Clomipramine v ERF)					
Foa 2005	12/33	19/37				0.71 [0.41, 1.23]
Subtotal (95% CI)	33	37				0.71 [0.41, 1.23]
Total events: 12 (ERP + SRI),	, 19 (ERP)			-		
Test for heterogeneity: not a	pplicable					
Test for overall effect: Z = 1	.23 (P = 0.22)					
			0.1 0.2	0.5 1 2	5 10	

Favours ERP+SRI Favours ERP

Favours ERP+SRI Favours ERP

Review: OCD: combination therapy Comparison: 01 ERP+ SRI v ERP

Outcome: 06 Global criterion of non-improvement (duration of rituals)

Study or sub-category	ERP + SRI n/N	ERP n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 ERP + Fluvoxamine v ERP +	placebo: post-treatment			
Cottraux 1990	9/20	14/20		0.64 [0.37, 1.13]
Subtotal (95% CI)	9/20	14/20		0.64 [0.37, 1.13]
Test for heterogeneity; not app	licable		-	·
Test for overall effect: Z = 1.54	4 (P = 0.12)			
02 ERP + Fluvoxamine v ERP +	placebo: 6 months follow-up)		
Cottraux 1990	11/20	14/20		0.79 [0.48, 1.28]
Subtotal (95% CI)	11/20	14/20		0.79 [0.48, 1.28]
Test for heterogeneity; not app	licable		_	
Test for overall effect: Z = 0.97	7 (P = 0.33)			
03 ERP + Fluvoxamine v ERP +	placebo: 1 year follow-up			
Cottraux 1990	11/20	12/20		0.92 [0.54, 1.56]
Subtotal (95% CI)	11/20	12/20	-	0.92 [0.54, 1.56]
Test for heterogeneity; not app	licable		7	
Test for overall effect: Z = 0.32				

OCD: combination therapy 01 ERP+ SRI v ERP 07 Y-BOCS Review: Comparison: Outcome:

Study or sub-category	N	ERP + SRI Mean (SD)	N	ERP Mean (SD)		SMD (f 95%			SMD (fixed) 95% Cl
01 ERP + Fluvoxamine v ERP									
van Balkom 1998	18	12.60(6.60)	19	17.10(8.40)		-			-0.58 [-1.24, 0.08]
Subtotal (95% CI)	18		19			•			-0.58 [-1.24, 0.08]
est for heterogeneity: not app	olicable								
est for overall effect: $Z = 1.7$	3 (P = 0.08)								
02 MBT + Fluvoxamine v MBT -	+ placebo								
Hohagen 1998	24	12.40(6.80)	25	15.90(7.90)		-			-0.47 [-1.03, 0.10]
Subtotal (95% CI)	24		25			•			-0.47 [-1.03, 0.10]
Fest for heterogeneity: not app	olicable					-			
est for overall effect: Z = 1.6	1 (P = 0.11)								
03 ERP + Clomipramine v ERP									
Foa 2005	19	10.50(8.20)	21	11.00(7.90)			_		-0.06 [-0.68, 0.56]
Subtotal (95% CI)	19		21			•	>		-0.06 [-0.68, 0.56]
est for heterogeneity: not app	olicable]			
est for overall effect: Z = 0.1	9 (P = 0.85)								
Total (95% CI)	61		65			•			-0.37 [-0.72, -0.01]
est for heterogeneity: Chi² = 1	1.46, df = 2 (P	' = 0.48), I ² = 0%				- 1			
est for overall effect: Z = 2.0	4 (P = 0.04)								
					-4	-2 0	2	4	
						urs ERP+SRI	Favours ERP		


Review: OCD: combination therapy Comparison: 01 ERP+ SRI v ERP Outcome: 08 Padua Inventory ERP + SRI **ERP** SMD (fixed) SMD (fixed) Study orsub-category Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 ERP + Fluvoxamine v ERP van Balkom 1998 43.20(23.50) 57.20(20.60) -0.62 [-1.28, 0.04] 19 18 Subtotal (95% CI) 18 19 -0.62 [-1.28, 0.04] Test for heterogeneity: not applicable Test for overall effect: Z = 1.84 (P = 0.07) Favours ERP+SRI Favours ERP OCD: combination therapy Review: 01 ERP+ SRI v ERP Comparison: 09 Depression scales (post treatment) Outcome: SMD (fixed) SMD (fixed) Study BT+ SRI BT Ν Mean (SD) or sub-category Ν Mean (SD) 95% CI 95% CI 01 ERP + Fluvoxamine v ERP -1.19 [-1.89, -0.48] -1.19 [-1.89, -0.48] van Balkom 1998 18 10.10(7.20) 19 19.90(8.80) Subtotal (95% CI) 18 19 Test for heterogeneity: not applicable Test for overall effect: Z = 3.30 (P = 0.0010) 02 MBT + Fluvoxamine v MBT + placebo Hohagen 1998 11.50(9.20) 25 14.00(10.20) -0.25 [-0.82, 0.31] Subtotal (95% CI) -0.25 [-0.82, 0.31] Test for heterogeneity: not applicable Test for overall effect: Z = 0.88 (P = 0.38) 03 ERP + Fluvoxamine v ERP + placebo Cottraux 1990 16 9.12(6.03) 15 15.13(5.74) -0.99 [-1.75, -0.24] Subtotal (95% CI) 16 15 -0.99 [-1.75, -0.24] Test for heterogeneity: not applicable Test for overall effect: Z = 2.59 (P = 0.010) 04 Exposure + Clomipramine v Exposure + placebo (at 7 weeks) Marks 1980 8.10(8.30) 10 16.50(11.10) -0.82 [-1.74, 0.10] 10 Subtotal (95% CI) -0.82 [-1.74, 0.10] Test for heterogeneity: not applicable Test for overall effect: Z = 1.75 (P = 0.08) 69 -0.73 [-1.08, -0.38] Test for heterogeneity: Chi² = 4.90, df = 3 (P = 0.18), l² = 38.8% Test for overall effect: Z = 4.07 (P < 0.0001)Favours BT+SRI Favours BT OCD: combination therapy Review: Comparison: 01 ERP+ SRI v ERP Outcome 10 Hamilton Depression Rating scale (follow-up) **ERP** SMD (fixed) Study ERP+ SRI SMD (fixed) N or sub-category Mean (SD) Mean (SD) 01 ERP + Fluvoxamine v ERP + placebo (6 months follow-up) Cottraux 1990 12.17(10.38) -0.17 [-0.94, 0.60] 14 10.71(6.27) 12 Subtotal (95% CI) -0.17 [-0.94, 0.60] Test for heterogeneity: not applicable Test for overall effect: Z = 0.43 (P = 0.67) 02 ERP + Fluvoxamine v ERP + placebo (1 year follow-up) Cottraux 1990 0.28 [-0.54, 1.10] 11.80(7.90) 11 9.50(7.90) Subtotal (95% CI) 11 0.28 [-0.54, 1.10] Test for heterogeneity; not applicable Test for overall effect: Z = 0.67 (P = 0.50) Favours ERP+SRI Favours ERP Review: OCD: combination therapy 01 ERP+ SRI v ERP Comparison: Outcome: 11 Symptom Checklist-90 SMD (fixed) BT + SRI ΒТ SMD (fixed) Study or sub-category Mean (SD) Mean (SD) 01 ERP + Fluvoxamine v ERP van Balkom 1998 184.30(55.50) -0.54 [-1.20, 0.11] 18 154.50(51.40) 19 Subtotal (95% CI) -0.54 [-1.20, 0.11] 18 19 Test for heterogeneity: not applicable Test for overall effect: Z = 1.62 (P = 0.10)

Favours BT+SRI Favours BT

Review: OCD: combination therapy Comparison: 01 ERP+ SRI v ERP Outcome: 12 Anxiety Discomfort Scale: patient's ratings ВΤ SMD (fixed) SMD (fixed) Study or sub-category Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 ERP + Fluvoxamine v ERP van Balkom 1998 13.00(4.90) 17.80(7.60) -0.73 [-1.40, -0.06] 18 19 Subtotal (95% CI) 18 19 -0.73 [-1.40, -0.06] Test for heterogeneity: not applicable Test for overall effect: Z = 2.14 (P = 0.03) Favours BT+SRI Favours BT OCD: combination therapy Review: Comparison: 01 ERP+ SRI v ERP Outcome: 13 Anxiety Discomfort Scale: therapist's ratings BT + SRI ВΤ SMD (fixed) SMD (fixed) Study Mean (SD) Ν Mean (SD) 95% CI 95% CI or sub-category Ν 01 ERP + Fluvoxamine v ERP van Balkom 1998 18 14.20(10.30) 19 20.60(10.50) -0.60 [-1.26, 0.06] Subtotal (95% CI) -0.60 [-1.26, 0.06] 18 19 Test for heterogeneity: not applicable Test for overall effect: Z = 1.79 (P = 0.07) Favours BT+SRI Favours BT Review: OCD: combination therapy Comparison: 01 ERP+ SRLv ERP 14 Anxiety Discomfort Scale: assessor's ratings Outcome: BT + SRI SMD (fixed) SMD (fixed) or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 ERP + Fluvoxamine v ERP van Balkom 1998 18 14.20(8.70) 19 19.40(8.70) -0.58 [-1.24, 0.08] Subtotal (95% CI) 19 -0.58 [-1.24, 0.08] Test for heterogeneity: not applicable Test for overall effect: Z = 1.74 (P = 0.08)Favours BT+SRI Favours BT Review: OCD: combination therapy 01 ERP+ SRI v ERP Comparison: Outcome: 15 Clinical Anxiety Scale ВΤ SMD (fixed) SMD (fixed) Study BT+ SRI or sub-category Mean (SD) Mean (SD) 95% CI 95% CI 01 MBT + Fluvoxamine v MBT + placebo -0.21 [-0.78, 0.35] Hohagen 1998 24 5.40(3.90) 25 6.40(5.20) Subtotal (95% CI) -0.21 [-0.78, 0.35] 24 25 Test for heterogeneity: not applicable Test for overall effect: Z = 0.74 (P = 0.46) Favours BT+SRI Favours BT Review: OCD: combination therapy 01 ERP+ SRLv ERP Comparison: 16 Global Assessment Scale Outcome: Study BT+ SRI ΒT SMD (fixed) SMD (fixed) or sub-category Mean (SD) Ν Mean (SD) 95% CL 95% CI 01 MBT + Fluvoxamine v MBT + placebo Hohagen 1998 -63.10(14.40) 25 -59.80(16.60) -0.21 [-0.77, 0.35] Subtotal (95% CI) 25 -0.21 [-0.77, 0.35] Test for heterogeneity: not applicable Test for overall effect: Z = 0.73 (P = 0.47) Favours BT+SRI Favours BT OCD: combination therapy Review: Comparison: 01 ERP+ SRI v ERP Outcome: 17 CGI - therapist rating BT+ SRI SMD (fixed) SMD (fixed) Study orsub-category N Mean (SD) Ν Mean (SD) 95% CI 01 MBT + Fluvoxamine v MBT + placebo Hohagen 1998 -7.90(1.40) -0.27 [-0.84. 0.29] 25 -7.40(2.10)24 -0.27 [-0.84, 0.29] Test for heterogeneity: not applicable Test for overall effect: Z = 0.96 (P = 0.34)

Favours BT+SRI Favours BT

Review: OCD: combination therapy Comparison: 01 ERP+ SRI v ERP 18 CGI - patient rating Outcome:



OCD: combination therapy Review: Comparison: 01 ERP+ SRI v ERP

Outcome: 19 Compulsive activity checklist (post treatment)

Study or sub-category	N	BT + SRI Mean (SD)	N	BT Mean (SD)		SMD (fixed) 95% Cl	SMD (fixed) 95% Cl	
01 ERP + Fluvoxamine v ER	P + placebo (pos	t treatment)						
Cottraux 1990	16	14.56(17.38)	15	24.33(18.36)			-0.53 [-1.25, 0.	19]
Subtotal (95% CI)	16		15				-0.53 [-1.25, 0.	19]
Test for heterogeneity: not	applicable					-		
Test for overall effect: Z = 1	1.45 (P = 0.15)							
02 Exposure + Clomipramino	e v Exposure + p	lacebo: assessor-rated (at	7 weeks)					
Marks 1980	10	20.10(15.60)	10	31.30(20.50)			-0.59 [-1.49, 0.	31]
Subtotal (95% CI)	10		10			-	-0.59 [-1.49, 0.	31]
Test for heterogeneity: not:	applicable							
Test for overall effect: Z = 1	1.28 (P = 0.20)							
Total (95% CI)	26		25			•	-0.55 [-1.12, 0.	01]
Test for heterogeneity: Chi ²	= 0.01, df = 1 (P	= 0.92), I ² = 0%						
Test for overall effect: Z = 1	1.94 (P = 0.05)							
					-4 -2	0 2	4	
					Favours B	T+SRI Favours BT		

Review: OCD: combination therapy Comparison: 01 ERP+ SRI v ERP

20 Compulsive activity checklist (follow-up) Outcome:

Study or sub-category	N	BT + SRI Mean (SD)	N	BT Mean (SD)			1D (fixed) 95% Cl			SMD (fixed) 95% Cl
01 ERP + Fluvoxamine v ER	RP + placebo (1 ye	ear follow-up)								
Cottraux 1990	12	15.50(17.60)	11	24.80(20.80)		_	-			-0.47 [-1.30, 0.36]
Subtotal (95% CI)	12		11							-0.47 [-1.30, 0.36]
Test for heterogeneity: not	applicable						-			
Test for overall effect: Z =	1.10 (P = 0.27)									
					-4	-2	0	2	4	

Favours BT+SRI Favours BT

Favours BT+SRI Favours BT

OCD: combination therapy Review:


Comparison: 01 ERP+ SRI v ERP

Outcome: 21 Target rituals (assessor): time (post-treatment)

Study or sub-category	N	BT + SRI Mean (SD)	N	BT Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl	
D1 ERP + Fluvoxamine v ERP	+ placebo (post	treatment)					
Cottraux 1990	16	8.50(7.30)	15	15.60(9.20)	 -	-0.84 [-1.57, -0.10]	
Subtotal (95% CI)	16		15		•	-0.84 [-1.57, -0.10]	
Test for heterogeneity: not a	pplicable						
Test for overall effect: $Z = 2$.22 (P = 0.03)						
02 Exposure + Clomipramine	v Exposure + pl	acebo (at 7 weeks)					
Marks 1980	10	2.10(2.10)	10	3.90(2.40)		-0.76 [-1.68, 0.15]	
Subtotal (95% Cl)	10		10			-0.76 [-1.68, 0.15]	
Test for heterogeneity: not a	pplicable				-		
Test for overall effect: $Z = 1$.64 (P = 0.10)						
Total (95% CI)	26		25		•	-0.81 [-1.38, -0.23]	
Test for heterogeneity: Chi ² :	= 0.01, df = 1 (P	= 0.91), I ² = 0%			-		
Test for overall effect: $Z = 2$.75 (P = 0.006)						

Review: OCD: combination therapy Comparison: 01 ERP+ SRI v ERP

Outcome: 22 Target rituals (assessor): time (follow-up)



Favours BT+SRI Favours BT

Favours BT+SRI Favours BT

Review: OCD: combination therapy

Comparison: 01 ERP+ SRI v ERP

Outcome: 23 Target rituals (assessor): discomfort (post-treatment)

Study or sub-category	N	BT + SRI Mean (SD)	N	BT Mean (SD)		SMD (fix 95% C		SMD (fixed) 95% Cl
01 ERP + Fluvoxamine v ER	RP + placebo (posi	t treatment)						
Cottraux 1990	16	10.25(8.04)	15	17.00(8.35)				-0.80 [-1.54, -0.07]
Subtotal (95% CI)	16		15			-		-0.80 [-1.54, -0.07]
Test for heterogeneity: not	applicable					-		
Test for overall effect: Z =	2.14 (P = 0.03)							
02 Exposure + Clomipramin	e v Exposure + pi	lacebo (at 7 weeks)						
Marks 1980	10	2.90(2.00)	10	4.90(1.80)				-1.01 [-1.95, -0.06]
Subtotal (95% CI)	10		10					-1.01 [-1.95, -0.06]
Test for heterogeneity: not	applicable					-		
Test for overall effect: Z =	2.09 (P = 0.04)							
Total (95% CI)	26		25			•		-0.88 [-1.46, -0.30]
Test for heterogeneity: Chi ²	² = 0.11, df = 1 (P	= 0.74), I ² = 0%				-		
Test for overall effect: Z =	2.97 (P = 0.003)							
					-4	-2 0	2	4
					Fav	vours BT+SRI F	avours BT	

Review: OCD: combination therapy Comparison: 01 ERP+ SRI v ERP

Outcome: 24 Target rituals (assessor): discomfort (follow-up)

itudy r sub-category	N	BT + SRI Mean (SD)	N	BT Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
1 ERP + Fluvoxamine v ERP -	⊦ placebo (6 mo	onths follow-up)				
Cottraux 1990	14	12.21(9.25)	12	13.30(9.80)	— 	-0.11 [-0.88, 0.66]
Subtotal (95% CI)	14		12		•	-0.11 [-0.88, 0.66]
est for heterogeneity: not ap	plicable				7	
est for overall effect: $Z = 0.2$	28 (P = 0.78)					
2 ERP + Fluvoxamine v ERP -	r placebo (1 ye	ear follow-up)				
Cottraux 1990	12	11.50(10.90)	11	11.00(9.10)	— 	0.05 [-0.77, 0.87]
Subtotal (95% CI)	12		11		•	0.05 [-0.77, 0.87]
est for heterogeneity; not ap	plicable				Т	·
est for overall effect: $Z = 0.1$	1 (P = 0.91)					

Review: OCD: combination therapy

Comparison: 01 ERP+ SRI v ERP

25 Target rituals (assessor): duration per day Outcome:

Study or sub-category	N	BT + SRI Mean (SD)	N	BT Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 ERP + Fluvoxamine v ERP + p	placebo (post	treatment)				
Cottraux 1990	16	3.93(2.26)	15	5.40(2.19)	-	-0.64 [-1.37, 0.08]
Subtotal (95% CI)	16		15		•	-0.64 [-1.37, 0.08]
Test for heterogeneity: not appli	licable				-	
Test for overall effect: $Z = 1.74$						
02 ERP + Fluvoxamine v ERP + p	placebo (6 mo	onths follow-up)				
Cottraux 1990	14	4.00(2.80)	12	4.67(2.27)	 _	-0.25 [-1.03, 0.52]
Subtotal (95% CI)	14		12		•	-0.25 [-1.03, 0.52]
Test for heterogeneity: not appli	licable				٦	
Test for overall effect: $Z = 0.64$	(P = 0.52)					
03 ERP + Fluvoxamine v ERP + p	placebo (1 ve	ar follow-up)				
Cottraux 1990	12	2.70(2.70)	11	3.30(2.70)	_ 	-0.21 [-1.04, 0.61]
Subtotal (95% CI)	12		11		•	-0.21 [-1.04, 0.61]
Test for heterogeneity: not appli	licable				7	•
Test for overall effect: Z = 0.51						
				-4	-2 0 2	4

Favours BT+SRI Favours BT

Favours BT+SRI Favours BT

OCD: combination therapy 01 ERP+ SRI v ERP Review:

Comparison:

Outcome: 26 Behavioural avoidance test: discomfort (post treatment)

Study or sub-category	N	BT + SRI Mean (SD)	N	BT Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
	RP + placebo (pos	t treatment)				
Cottraux 1990	16	9.12(6.55)	15	15.61(7.61)	 -	-0.89 [-1.64, -0.15]
Subtotal (95% CI)	16		15		-	-0.89 [-1.64, -0.15]
Test for heterogeneity: not	: applicable				-	
Test for overall effect: Z =	2.35 (P = 0.02)					
02 Exposure + Clomipramin	ne v Exposure + p	lacebo (at 7 weeks)				
Marks 1980	10	15.40(11.90)	10	16.90(10.00)		-0.13 [-1.01, 0.75]
Subtotal (95% CI)	10		10		-	-0.13 [-1.01, 0.75]
est for heterogeneity: not	: applicable				T	
est for overall effect: Z =	0.29 (P = 0.77)					
otal (95% CI)	26		25		•	-0.57 [-1.14, -0.01]
est for heterogeneity: Chi	i ² = 1.69, df = 1 (P	= 0.19), I ² = 40.7%			•	
「est for overall effect: Z =	1.98 (P = 0.05)	**				
Test for overall effect. 2 =	1.50 (1 = 0.00)			-4	-2 0 2	4

OCD: combination therapy Review:

Comparison:


Outcome: 27 Behavioural avoidance test: discomfort (follow-up)

Study or sub-category	N	BT + SRI Mean (SD)	N	BT Mean (SD)			MD (fixed) 95% CI)		SMD (fixed) 95% Cl
01 ERP + Fluvoxamine v EF	RP + placebo (1 ye	ear follow-up)								
Cottraux 1990	12	10.20(9.20)	11	11.50(9.20)		-	_			-0.14 [-0.96, 0.68]
Subtotal (95% CI)	12		11				-			-0.14 [-0.96, 0.68]
Test for heterogeneity: not	applicable						T			,
Test for overall effect: Z =	0.33 (P = 0.74)									
					-4	-2	-	2	4	
					Fa	vours BT+S	RI Fav	ours BT		

Review: OCD: combination therapy

Comparison: 02 ERP + Clomipramine v Clomipramine


01 Leaving the study early Outcome:



OCD: combination therapy Review:

02 ERP + Clomipramine v Clomipramine Comparison:

03 Non-responders (CGI) Outcome:



Favours BT+CMI Favours CMI

Favours BT+CMI Favours CMI

Favours ERP+FLV Favours Anti-ERP+FLV

Review:

OCD: combination therapy 02 ERP + Clomipramine v Clomipramine 05 Y-BOCS Comparison:

Outcome:

Study or sub-category	N B	T + Clomipramine Mean (SD)	N	Clomipramine Mean (SD)			(fixed) 6 Cl		SMD (fixed) 95% Cl
Foa 2005	19	10.50(8.20)	27	18.20(7.80)		-			-0.95 [-1.57, -0.33]
Total (95% CI)	19		27			•			-0.95 [-1.57, -0.33]
Test for heterogeneity: no	t applicable								
Test for overall effect: Z =	3.00 (P = 0.003)								
					-4	-2 1	<u> </u>	2	4

Review: OCD: combination therapy

03 ERP + Fluvoxamine v Anti-ERP + Fluvoxamine Comparison:

01 Leaving the study early Outcome:

Study or sub-category	ERP+Fluvoxamine n/N	Anti-ERP+Fluvoxamine n/N	RR (fixed 95% CI	•	RR (fixed) 95% Cl
Cottraux 1990	4/20	7/20	-	-	0.57 [0.20, 1.65]
Total (95% CI) Test for heterogeneity: not Test for overall effect: Z =	• •	7/20		-	0.57 [0.20, 1.65]
		0.1	0.2 0.5 1	2 5 10	

OCD: combination therapy Review:

03 ERP + Fluvoxamine v Ánti-ERP + Fluvoxamine Comparison: Outcome: 02 Leaving the study early due to adverse effects

Study or sub-category	ERP+Fluvoxamine n/N	Anti-ERP+Fluvoxamine n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
Cottraux 1990	2/20	2/20		1.00 [0.16, 6.42]
Total (95% CI) Test for heterogeneity: not applicate for overall effect: Z = 0.00 (F		2/20		1.00 [0.16, 6.42]
			0.1 0.2 0.5 1 2 5 10 Favours ERP+FLV Favours Anti-ERP+F	

Review: OCD: combination therapy

03 ERP + Fluvoxamine v Anti-ERP + Fluvoxamine Comparison:

03 Global criterion of non-improvement (duration of rituals) Outcome:

Study or sub-category	ERP+Flu∨oxamine n/N	Anti-ERP+Fluvoxamine n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Post-treatment				
Cottraux 1990	9/20	13/20		0.69 [0.39, 1.24]
Subtotal (95% CI)	9/20	13/20		0.69 [0.39, 1.24]
Test for heterogeneity: not app	olicable		-	·
Test for overall effect: $Z = 1.2$	4 (P = 0.22)			
02.6 months follow-up				
Cottraux 1990	11/20	15/20		0.73 [0.46, 1.17]
Subtotal (95% CI)	11/20	15/20	•	0.73 [0.46, 1.17]
Test for heterogeneity; not app	olicable		-	
Test for overall effect: $Z = 1.2$	9 (P = 0.20)			
03.1 year follow-up				
Cottraux 1990	11/20	14/20		0.79 [0.48, 1.28]
Subtotal (95% CI)	11/20	14/20		0.79 [0.48, 1.28]
Test for heterogeneity; not app				
Test for overall effect: Z = 0.9				

Favours ERP+FLV Favours Anti-ERP+FLV

Review:

OCD: combination therapy 03 ERP + Fluvoxamine v Anti-ERP + Fluvoxamine Comparison:

04 Hamilton Depression Scale Outcome:

tudy r sub-category	N E	RP+Fluvoxamine Mean (SD)	Anti N	-ERP+Fluvoxamine Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
1 Post treatment						
Cottraux 1990	16	9.12(6.03)	13	10.46(6.98)	=	-0.20 [-0.94, 0.53]
ubtotal (95% CI)	16		13		•	-0.20 [-0.94, 0.53]
est for heterogeneity: not a	pplicable				1	
est for overall effect: Z = 0	.54 (P = 0.59)					
2.6 months follow-up						
Cottraux 1990	14	10.71(6.27)	11	11.27(6.02)	=	-0.09 [-0.88, 0.70]
ubtotal (95% CI)	14		11		•	-0.09 [-0.88, 0.70]
st for heterogeneity: not a	pplicable					
est for overall effect: Z = 0	.22 (P = 0.83)					
3.1 year follow-up						
Cottraux 1990	12	11.80(7.90)	10	8.50(3.80)		0.50 [-0.36, 1.35]
ubtotal (95% CI)	12		10		₩	0.50 [-0.36, 1.35]
est for heterogeneity: not a	pplicable				ľ	
est for overall effect: Z = 1	.14 (P = 0.25)					

Favours ERP + FLV Favours Anti-ERP+FLV

Review:

OCD: combination therapy 03 ERP + Fluvoxamine v Anti-ERP + Fluvoxamine 05 Target rituals (assessor): time Comparison:

Outcome:

Study	EF	RP+Fluvoxamine	Anti	i-ERP+Fluvoxamine	SMD (fixed)	SMD (fixed)
or sub-category	N	Mean (SD)	N	Mean (SD)	95% CI	95% CI
01 Post treatment						
Cottraux 1990	16	8.50(7.30)	13	12.84(7.78)		-0.56 [-1.31, 0.19]
Subtotal (95% CI)	16		13		•	-0.56 [-1.31, 0.19]
Test for heterogeneity: not a	pplicable				-	
Test for overall effect: $Z = 1$.47 (P = 0.14)					
02 6 months follow-up						
Cottraux 1990	14	10.30(8.70)	11	13.50(3.11)		-0.45 [-1.25, 0.35]
Subtotal (95% CI)	14		11		-	-0.45 [-1.25, 0.35]
Test for heterogeneity: not a	pplicable				-	
est for overall effect: $Z = 1$.10 (P = 0.27)					
03.1 year follow-up						
Cottraux 1990	12	9.70(9.90)	10	11.40(9.40)		-0.17 [-1.01, 0.67]
Subtotal (95% CI)	12		10		•	-0.17 [-1.01, 0.67]
Test for heterogeneity: not a	applicable				1	
Test for overall effect: $Z = 0$.39 (P = 0.69)					

Favours ERP+FLV Favours Anti-ERP+FLV

Review:

OCD: combination therapy 03 ERP + Fluvoxamine v Anti-ERP + Fluvoxamine Comparison: Outcome: 06 Target rituals (assessor): discomfort

Study or sub-category	N E	RP+Fluvoxamine Mean (SD)	Anti N	-ERP+Fluvoxamine Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Post treatment						
Cottraux 1990	16	10.25(8.04)	13	11.30(10.27)	_ _	-0.11 [-0.84, 0.62]
Subtotal (95% CI)	16		13		•	-0.11 [-0.84, 0.62]
Test for heterogeneity: not applicab	le				T	
Test for overall effect: Z = 0.30 (P =	= 0.76)					
02.6 months follow-up						
Cottraux 1990	14	12.21(9.25)	11	13.18(8.50)	— —	-0.11 [-0.90, 0.69]
Subtotal (95% CI)	14		11		•	-0.11 [-0.90, 0.69]
Test for heterogeneity: not applicab	ile				Ī	
Test for overall effect: $Z = 0.26$ (P =	= 0.79)					
03.1 year follow-up						
Cottraux 1990	12	11.50(10.90)	10	9.60(8.60)	_ 	0.18 [-0.66, 1.03]
Subtotal (95% CI)	12		10		-	0.18 [-0.66, 1.03]
Test for heterogeneity: not applicab	ile				T	,
Test for overall effect: Z = 0.43 (P =	= 0.67)					
				-4	-2 0 2	4

Favours ERP+FLV Favours Anti-ERP+FLV

Favours ERP+FLV Favours Anti-ERP+FLV

Favours ERP+FLV Favours Anti-ERP+FLV

Review:

OCD: combination therapy 03 ERP + Fluvoxamine v Anti-ERP + Fluvoxamine 07 Target rituals (assessor): duration per day Comparison: Outcome:

Study or sub-category	N Ef	RP+Fluvoxamine Mean (SD)	Anti- N	ERP+Fluvoxamine Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Post treatment						
Cottraux 1990	16	3.93(2.26)	13	4.07(2.56)	_ 	-0.06 [-0.79, 0.68]
Subtotal (95% CI)	16		13		•	-0.06 [-0.79, 0.68]
est for heterogeneity: not a	applicable				T	·
Test for overall effect: Z = 0).15 (P = 0.88)					
02 6 months follow-up						
Cottraux 1990	14	4.00(2.80)	11	4.09(2.59)		-0.03 [-0.82, 0.76]
Subtotal (95% CI)	14		11		•	-0.03 [-0.82, 0.76]
est for heterogeneity; not a	applicable				T	
est for overall effect: Z = 0	0.08 (P = 0.94)					
03.1 year follow-up						
Cottraux 1990	12	2.70(2.70)	10	3.20(3.10)	_ _	-0.17 [-1.01, 0.67]
Subtotal (95% CI)	12		10		-	-0.17 [-1.01, 0.67]
Test for heterogeneity: not a	applicable				7	
est for overall effect: $Z = 0$).39 (P = 0.70)					

Review:

OCD: combination therapy 03 ERP + Fluvoxamine v Anti-ERP + Fluvoxamine 08 Behavioural avoidance test: discomfort Comparison: Outcome:

itudy r sub-category	N EI	RP+Fluvoxamine Mean (SD)	Anti N	-ERP+Fluvoxamine Mean (SD)	SMD (fi 95%			SMD (fixed) 95% Cl
11 Post treatment								
Cottraux 1990	16	9.12(6.55)	13	11.46(6.75)	_	-	-0.34	[-1.08, 0.40]
Subtotal (95% CI)	16	,,	13	,	•			[-1.08, 0.40]
est for heterogeneity: not ap	oplicable				_			
est for overall effect: Z = 0.								
2.1 year follow-up								
Cottraux 1990	12	10.20(9.20)	10	10.30(9.40)		_	-0.01	[-0.85, 0.83]
Subtotal (95% CI)	12		10			-	-0.01	[-0.85, 0.83]
est for heterogeneity: not ap	oplicable				T			,
est for overall effect: Z = 0.	02 (P = 0.98)							

Review: OCD: combination therapy

03 ERP + Fluvoxamine v Anti-ERP + Fluvoxamine Comparison:

Outcome: 09 Compulsive activity checklist

Study or sub-category	E N	RP+Fluvoxamine Mean (SD)	Anti N	i-ERP+Fluvoxamine Mean (SD)		SMD (fixed) 95% Cl		SMD (fixed) 95% CI
01 Post treatment						_		
Cottraux 1990	16	14.56(17.38)	13	21.53(12.56)		_		-0.44 [-1.18, 0.30]
Subtotal (95% Cl)	16		13			-		-0.44 [-1.18, 0.30]
Test for heterogeneity: not a	applicable							
Test for overall effect: $Z = 1$	1.16 (P = 0.25)							
02.1 year follow-up								
Cottraux 1990	12	15.50(17.60)	10	20.70(14.30)		_		-0.31 [-1.15, 0.54]
Subtotal (95% CI)	12		10			•		-0.31 [-1.15, 0.54]
Test for heterogeneity: not a	applicable					_		•
Test for overall effect: Z = 0								
					-4	-2 0	2 4	

Favours ERP+FLV Favours Anti-ERP+FLV

OCD: combination therapy 04 CT + Fluvoxamine v CT Review:

Comparison: 01 Leaving the study early Outcome:

Study or sub-category	CT + Fluvoxamine n/N	CT n/N		RR (fixed) 95% Cl)		RR (fixed) 95% CI
van Balkom 1998	10/24	6/25		+	_		1.74 [0.75, 4.03]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 1	• •	6/25		-			1.74 [0.75, 4.03]
			0.1 0.2	0.5 1	2 5	10	

Favours CT+FLV Favours CT

Favours CT+FLV Favours CT

OCD: combination therapy 04 CT + Fluvoxamine v CT Review: Comparison:

Outcome: 02 Y-BOCS

Study or sub-category	N C	CT + Fluvoxamine Mean (SD)	N	CT Mean (SD)		SMD (fixed) 95% Cl	SMD (fixed) 95% CI
van Balkom 1998	14	15.60(5.40)	19	13.50(9.70)	_	-	0.25 [-0.44, 0.94]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 0			19		-		0.25 [-0.44, 0.94]
					-1 -0.5	0 0.5 1	

OCD: combination therapy 04 CT + Fluvoxamine v CT 03 Padua Inventory Review: Comparison: Outcome:

Study or sub-category	N C	T + Fluvoxamine Mean (SD)	N	CT Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% CI
van Balkom 1998	14	43.50(18.40)	19	49.10(23.60)		-0.25 [-0.95, 0.44]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 0			19			-0.25 [-0.95, 0.44]
					-1 -0.5 0 0.5 Favours CT+FLV Favours CT	1

Review: OCD: combination therapy 04 CT + Fluvoxamine v CT 04 Beck Depression Inventory Comparison: Outcome:

Study or sub-category	C N	T + Fluvoxamine Mean (SD)	N	CT Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
van Balkom 1998	14	10.80(6.60)	19	9.90(7.00)		0.13 [-0.56, 0.82]
Total (95% CI) Test for heterogeneity: not ap Test for overall effect: Z = 0:			19			0.13 [-0.56, 0.82]
					-1 -0.5 0 0.5 1	
					Favours CT+FLV Favours CT	

Review: OCD: combination therapy 04 CT + Fluvoxamine v CT 05 Symptom Checklist-90 Comparison: Outcome:

Study or sub-category	N	CT + Fluvoxamine Mean (SD)	N	CT Mean (SD)		SMD (fixed) 95% Cl		SMD (fixed) 95% Cl
van Balkom 1998	14	162.00(42.70)	19	163.40(44.40)				-0.03 [-0.72, 0.66]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 0			19					-0.03 [-0.72, 0.66]
					-1	-0.5	0.5	1

Favours CT+FLV Favours CT

Favours CT+FLV Favours CT

Favours CT+FLV Favours CT

Favours CT+FLV Favours CT

Favours ERP+FLV Favours CT+FLV

OCD: combination therapy Review: Comparison: 04 CT + Fluvoxamine v CT

Outcome: 06 Anxiety Discomfort Scale: patient's ratings

Study or sub-category	N C	T + Fluvoxamine Mean (SD)	N	CT Mean (SD)		SMD (1 95%		SMD (fixed) 95% Cl
van Balkom 1998	14	13.00(4.90)	19	12.50(9.30)				0.06 [-0.63, 0.75]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 0			19					0.06 [-0.63, 0.75]
					-1	-0.5	0.5	1

OCD: combination therapy 04 CT + Fluvoxamine v CT 07 Anxiety Discomfort Scale: therapist's ratings Review: Comparison: Outcome:

Study or sub-category	N	T + Fluvoxamine Mean (SD)	N	CT Mean (SD)			MD (fixed) 95% CI)		MD (fixed) 95% Cl
van Balkom 1998	14	13.60(7.50)	19	13.10(10.20)			-		0.05 [-	0.64, 0.74]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 0			19				-	 -	0.05 [-	0.64, 0.74]
					-1	-0.5	Ó	0.5	1	

Review: OCD: combination therapy Comparison: 04 CT + Fluvoxamine v CT

08 Anxiety Discomfort Scale: assessor's ratings Outcome:

Study or sub-category	N C	T + Fluvoxamine Mean (SD)	N	CT Mean (SD)			MD (fixed) 95% Cl	SMD (fixed) 95% Cl
van Balkom 1998	14	13.80(4.70)	19	12.50(9.50)			-	0.16 [-0.53, 0.85]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 0			19		,	- 		0.16 [-0.53, 0.85]
					-1	-0.5	0 0.5	1

OCD: combination therapy Review:

Comparison: 05 ERP + Fluvoxamine v CT + Fluvoxamine

Outcome: 01 Leaving the study early

Study or sub-category	ERP + Fluvoxamine n/N	CT + Fluvoxamine n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
van Balkom 1998	10/28	10/24	_	0.86 [0.43, 1.70]
Total (95% CI) Test for heterogeneity: not appl Test for overall effect: Z = 0.44		10/24		0.86 [0.43, 1.70]
		0.1	0.2 0.5 1 2 5	10

OCD: combination therapy

05 ERP + Fluvoxamine v CT + Fluvoxamine 02 Y-BOCS Comparison:

Outcome:

Study or sub-category	EF N	RP + Fluvoxamine Mean (SD)	N C	T + Fluvoxamine Mean (SD)		S	SMD (fixed 95% Cl	1)		SMD (fixed) 95% CI
van Balkom 1998	18	12.60(6.60)	14	15.60(5.40)		_	-			-0.48 [-1.19, 0.23]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 1			14			-	•			-0.48 [-1.19, 0.23]
Total of Oyol all office. 2 = 1.	.02 (1 = 0.10)				-4	-2 urs ERP+F	0	2 /ours CT+F	4	

Review: OCD: combination therapy Comparison: 05 ERP + Fluvoxamine v CT + Fluvoxamine 03 Padua Inventory Outcome: ERP + Fluvoxamine CT + Fluvoxamine SMD (fixed) SMD (fixed) Study or sub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CI van Balkom 1998 18 43.20(23.50) 43.50(18.40) -0.01 [-0.71, 0.68] 14 Total (95% CI) 18 14 -0.01 [-0.71, 0.68] Test for heterogeneity: not applicable Test for overall effect: Z = 0.04 (P = 0.97) -0.5 0.5 Favours ERP+FLV Favours CT+FLV Review: OCD: combination therapy 05 ERP + Fluvoxamine v CT + Fluvoxamine Comparison: Outcome: 04 Beck Depression Inventory SMD (fixed) SMD (fixed) Study ERP + Fluvoxamine CT + Fluvoxamine Ν 95% CI 95% CI or sub-category Ν Mean (SD) Mean (SD) van Balkom 1998 18 10.10(7.20) 14 10.80(6.60) -0.10 [-0.80, 0.60] Total (95% CI) -0.10 [-0.80, 0.60] 18 14 Test for heterogeneity: not applicable Test for overall effect: Z = 0.28 (P = 0.78) 0.5 -0.5 Favours ERP+FLV Favours CT+FLV Review: OCD: combination therapy Comparison: 05 ERP + Fluvoxamine v CT + Fluvoxamine Outcome: 05 Symptom Checklist-90 SMD (fixed) SMD (fixed) ERP + Fluvoxamine CT + Fluvoxamine or sub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CI van Balkom 1998 154.50(51.40) 162.00(42.70) -0.15 [-0.85, 0.55] 18 14 Total (95% CI) 14 -0.15 [-0.85, 0.55] Test for heterogeneity: not applicable Test for overall effect: Z = 0.43 (P = 0.67)-0.5 0.5 Favours ERP+FLV Favours CT+FLV OCD: combination therapy Review: Comparison: 05 ERP + Fluvoxamine v CT + Fluvoxamine Outcome 06 Anxiety Discomfort Scale: patient's ratings SMD (fixed) SMD (fixed) Study ERP + Fluvoxamine CT + Fluvoxamine 95% CI 95% CI or sub-category Mean (SD) Mean (SD) van Balkom 1998 18 13.00(4.90) 14 13.00(4.90) 0.00 [-0.70, 0.70] Total (95% CI) 0.00 [-0.70, 0.70] 18 14 Test for heterogeneity: not applicable Test for overall effect: Z = 0.00 (P = 1.00)-0.5 0.5 Favours ERP+FLV Favours CT+FLV Review: OCD: combination therapy 05 ERP + Fluvoxamine v CT + Fluvoxamine Comparison 07 Anxiety Discomfort Scale: therapist's ratings Outcome: Study ERP + Fluvoxamine CT + Fluvoxamine SMD (fixed) SMD (fixed) or sub-category Ν Mean (SD) Ν Mean (SD) 95% CL 95% CL van Balkom 1998 18 14.20(10.30) 14 13.60(7.50) 0.06 [-0.64, 0.76] Total (95% CI) 18 14 0.06 [-0.64, 0.76] Test for heterogeneity: not applicable Test for overall effect: Z = 0.18 (P = 0.86)

Comparison: 05 ERP + Fluvoxamine v CT + Fluvoxamine Outcome: 08 Anxiety Discomfort Scale: assessor's ratings ERP + Fluvoxamine SMD (fixed) SMD (fixed) Study CT + Fluvoxamine or sub-category N Mean (SD) N Mean (SD) 95% CI 0.05 [-0.64, 0.75] van Balkom 1998 18 14.20(8.70) 14 13.80(4.70) Total (95% CI) 14 0.05 [-0.64, 0.75] Test for heterogeneity: not applicable Test for overall effect: Z = 0.15 (P = 0.88)

-0.5

Favours ERP+FLV

-0.5

Favours ERP+FLV

Ó

0.5

0.5

Favours CT+FLV

Favours CT+FLV

OCD: combination therapy

Review:

Review: OCD: combination therapy

06 Children: ERP + Fluvoxamine v Fluvoxamine alone Comparison: 01 Non-responder (Y-BOCS reliable change) Outcome:

0/5 0/5	3/5 3/5	-	0.14 [0.01, 2.21] 0.14 [0.01, 2.21]
-	·	-	
0/5	3/5		0.14 [0.01, 2.21]
			·
0/5	2/5		0.20 [0.01, 3.35]
0/5	2/5		0.20 [0.01, 3.35]
			·
0/5	2/5		0.20 [0.01, 3.35]
0/5	2/5		0.20 [0.01, 3.35]
		- -	•
)/5)/5	1/5 2/5 1/5 2/5 1/5 2/5	1/5 2/5

Favours ERP+FLV Favours FLV

OCD: combination therapy Review:

Comparison: 06 Children: ERP + Fluvoxamine v Fluvoxamine alone

02 CY-BOCS Outcome:

Study or sub-category	N E	ERP + Fluvoxamine Mean (SD)	N	Fluvoxamine Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 At 43 weeks Neziroqlu 2000	5	11 6045 645		2 6044 205	_	1 44 1 2 00 0 041
Subtotal (95% CI)	5	-11.60(5.64)	5	-3.60(4.28)		-1.44 [-2.93, 0.04] -1.44 [-2.93, 0.04]
Test for heterogeneity: not applicable						-1.44 [-2.93, 0.04]
Test for overall effect: $Z = 1.91$ (P =	0.06)					
02 At 52 weeks						
Neziroglu 2000	5	-14.00(6.08)	5	-3.40(6.69)		-1.50 [-3.00, 0.00]
Subtotal (95% CI)	- 5		5			-1.50 [-3.00, 0.00]
Test for heterogeneity: not applicable	9				_	
Test for overall effect: $Z = 1.96$ (P =	0.05)					
03 At 2 years						
Neziroglu 2000	5	-20.20(2.17)	5	-9.00(11.42)		-1.23 [-2.65, 0.19]
Subtotal (95% CI)	- 5		5			-1.23 [-2.65, 0.19]
Test for heterogeneity: not applicable	Э				-	
Test for overall effect: $Z = 1.70$ (P =	0.09)					
					-4 -2 0 2	4

Favours ERP+FLV Favours FLV Review: OCD: combination therapy

06 Children: ERP + Fluvoxamine v Fluvoxamine alone 03 NIMH-GOCS Comparison:


Outcome:

Study or sub-category I	EF N	RP + Fluvoxamine Mean (SD)	N	Fluvoxamine Mean (SD)		SMD (fixed) 95% Cl	ı	SMD (fixed) 95% Cl
01 At 43 weeks								
Neziroglu 2000	5	-4.00(1.58)	5	-2.80(2.39)		_		-0.54 [-1.81, 0.74]
ubtotal (95% CI)	5		5			-		-0.54 [-1.81, 0.74]
est for heterogeneity: not applicable	9					7		
est for overall effect: Z = 0.82 (P =								
2 At 52 weeks								
Neziroglu 2000	5	-3.80(2.17)	5	-2.20(2.39)		_		-0.63 [-1.92, 0.66]
ubtotal (95% CI)	5		5			•		-0.63 [-1.92, 0.66]
est for heterogeneity: not applicable	9							•
est for overall effect: Z = 0.96 (P =								
3 At 2 years								
Neziroglu 2000	5	-7.40(2.88)	5	-4.00(4.53)		-		-0.81 [-2.13, 0.51]
ubtotal (95% CI)	5		5			•		-0.81 [-2.13, 0.51]
est for heterogeneity: not applicable	9					1		
est for overall effect: Z = 1.20 (P =	0.23)							
					-10	-5 0	5 10	
					Favours	s ERP+FLV Fav	ours FLV	

OCD: combination therapy Review:

07 Children: CBT + Sertraline v Sertraline Comparison:

01 Leaving the study early Outcome:



Favours CBT+Sertrali Favours Sertraline

Review: OCD: combination therapy

07 Children: CBT + Sertraline v Sertraline Comparison:

Outcome: 02 Leaving the study early due to adverse events

Study or sub-category	CBT + Sertraline n/N	Sertraline n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
POTS 2004	1/28	1/28	•	1.00 [0.07, 15.21]
Total (95% CI) Test for heterogeneity: not Test for overall effect: Z =	• •	1/28		1.00 [0.07, 15.21]
			0.1 0.2 0.5 1 2 5 10	

Favours CBT+Sertrali Favours Sertraline

Review:

OCD: combination therapy 07 Children: CBT + Sertraline v Sertraline Comparison:

Outcome: 03 CY-BOCS

Study or sub-category	N	CBT + Sertraline Mean (SD)	N	Sertraline Mean (SD)		SMD (fixed) 95% Cl	SMD (fixed) 95% CI	
POTS 2004	28	11.20(8.60)	28	16.50(9.10)	←		-0.59 [-1.13, -0.05]	
Total (95% CI) Test for heterogeneity: not Test for overall effect: Z =			28				-0.59 [-1.13, -0.05]	
					-1 -0.5	0 0.5	5 1	

Favours CBT+Sertrali Favours Sertraline

OCD: combination therapy Review: Comparison: 08 Children: CBT + Sertraline v CBT

Outcome: 01 Leaving the study early

Study or sub-category	CBT + Sertraline n/N	Sertraline n/N		(fixed) 5% Cl	RR (fixed) 95% Cl
POTS 2004	3/28	3/28		-	1.00 [0.22, 4.54]
Total (95% CI) Test for heterogeneity: not Test for overall effect: Z =	• •	3/28			1.00 [0.22, 4.54]
			0.1 0.2 0.5	1 2 5	10

Favours CBT+Sertrali Favours Sertraline

OCD: combination therapy Review: Comparison: 08 Children: CBT + Sertraline v CBT

Outcome: 02 CY-BOCS

Study or sub-category	N	CBT + Sertraline Mean (SD)	N	Sertraline Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
POTS 2004	28	11.20(8.60)	28	14.00(9.50)		-0.30 [-0.83, 0.22]
Total (95% CI) Test for heterogeneity: no Test for overall effect: Z =			28			-0.30 [-0.83, 0.22]
					-1 -0.5 0 0.5	1


Favours CBT+Sertrali Favours Sertraline

Other medical interventions

Review: OCD: other medical

01 Stereotactic anterior capsulotomy vs cingulotomy 01 CPRS @ 3 months: change score Comparison:

Outcome:



Review: OCD: other medical

Comparison: 01 Stereotactic anterior capsulotomy vs cingulotomy

Outcome: 02 CPRS @ 6 months: change score

Study or sub-category	N	Capsulotomy Mean (SD)	N	Cingulotomy Mean (SD)			(fixed) 5% Cl		SMD (fixed) 95% Cl
Fodstad 1982	2	-13.25(5.30)	2	-11.25(1.06)				_	-0.30 [-2.89, 2.29]
Total (95% CI) Test for heterogeneity: not Test for overall effect: Z =			2					•-	-0.30 [-2.89, 2.29]
					-4	-2	0	2	4

Review: OCD: other medical

Comparison: 01 Stereotactic anterior capsulotomy vs cingulotomy

Outcome: 03 CPRS @ 12 months: change score

Fodstad 1982 2 -13.50(2.83) 2 -17.25(6.01)	95% CI
	0.46 [-2.78, 3.70]
Total (95% CI) 2 2 Test for heterogeneity: not applicable Test for overall effect: Z = 0.28 (P = 0.78)	0.46 [-2.78, 3.70]

Review: OCD: other medical

Comparison: 01 Stereotactic anterior capsulotomy vs cingulotomy

Outcome: 04 HAM-D @ 3 months; change score

Study or sub-category	N	Capsulotomy Mean (SD)	N	Cingulotomy Mean (SD)		S	MD (fixed) 95% Cl	ı		SMD (fixed) 95% CI
Fodstad 1982	2	-3.00(4.24)	2	-4.00(0.01)			-			0.19 [-2.05, 2.43]
Total (95% CI) Test for heterogeneity: no Test for overall effect: Z =			2							0.19 [-2.05, 2.43]
					-4	-2	ó	2	4	

OCD: other medical Review:

01 Stereotactic anterior capsulotomy vs cingulotomy Comparison:

Outcome: 05 HAM-D @ 6 months: change score

Study or sub-category	N	Capsulotomy Mean (SD)	N	Cingulotomy Mean (SD)			MD (fixed) 95% Cl			SMD (fixed) 95% Cl
Fodstad 1982	2	-2.00(5.66)	2	-2.00(2.83)			+	_		0.00 [-1.96, 1.96]
Total (95% CI) Test for heterogeneity: not Test for overall effect: Z =			2				+			0.00 [-1.96, 1.96]
					-4	-2	ó	2	4	

Comparison: 01 Stereotactic anterior capsulotomy vs cingulotomy

06 HAM-D @ 12 months: change score Outcome:

Study or sub-category	N	Capsulotomy Mean (SD)	N	Cingulotomy Mean (SD)		SMD (fixe 95% CI		SMD (fixed) 95% Cl
Fodstad 1982	2	-1.50(4.95)	2	-4.50(0.71)				0.48 [-2.89, 3.86]
Total (95% CI) Test for heterogeneity: not Test for overall effect: Z =			2					0.48 [-2.89, 3.86]
					-4	-2 0	2 4	

Favours capsulotomy Favours cingulotomy

Favours capsulotomy Favours cinquiotomy

Favours capsulotomy Favours cingulotomy

Favours capsulotomy Favours cingulotomy

Review: OCD: other medical

Comparison: 01 Stereotactic anterior capsulotomy vs cingulotomy

07 HAM-A @ 3 months; change score Outcome:

Study or sub-category	N	Capsulotomy Mean (SD)	N	Cingulotomy Mean (SD)			ID (fixed) 95% CI			SMD (fixed) 95% Cl
Fodstad 1982	2	-4.00(1.41)	2	-11.50(12.02)	-		-		_	0.50 [-2.94, 3.95]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 0.			2						- -	0.50 [-2.94, 3.95]
					-4	-2	ó	2	4	

Favours capsulotomy Favours cingulotomy

Favours capsulotomy Favours cingulotomy

Favours capsulotomy Favours cingulotomy

OCD: other medical Review:

Comparison: 01 Stereotactic anterior capsulotomy vs cingulotomy

Outcome: 08 HAM-A @ 6 months: change score

Study or sub-category	N	Capsulotomy Mean (SD)	N	Cingulotomy Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% CI
Fodstad 1982	2	-3.00(2.83)	2	-6.00(5.66)	-	 0.38 [-2.54, 3.31]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 0			2			0.38 [-2.54, 3.31]

Review: OCD: other medical

01 Stereotactic anterior capsulotomy vs cingulotomy 09 HAM-A @ 12 months; change score Comparison:

Outcome:

Study or sub-category	N	Capsulotomy Mean (SD)	N	Cingulotomy Mean (SD)) (fixed) 5% Cl			SMD (fixed) 95% Cl
Fodstad 1982	2	-2.50(3.54)	2	-7.50(7.78)			-		_	0.47 [-2.84, 3.79]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 0.			2						-	0.47 [-2.84, 3.79]
					-4	-2	Ó	ż	4	

OCD: other medical Review:

Comparison: 02 Repetitive transcranial magnetic stimulation; active vs placebo


Outcome: 01 Adverse effects

Study or sub-category	Active RTMS n/N	Placebo RTMS n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
Alonso 2001	1/10	0/8		2.45 [0.11, 53.25]
Total (95% CI) Total events: 1 (Active RTM Test for heterogeneity: not a Test for overall effect: Z = 0	applicable	8		2.45 [0.11, 53.25]
			0.01 0.1 1 10 10	0
			Favours active RTMS Favours placebo RT	'MS

Review: OCD: other medical

Comparison: 02 Repetitive transcranial magnetic stimulation; active vs placebo

Outcome: 02 Non-responders (Y-BOCS 40%)



Favours active RTMS Favours placebo RTMS

Review: OCD: other medical Comparison: 02 Repetitive transcranial magnetic stimulation; active vs placebo Outcome: 03 Y-BOCS; change score Active RTMS Placebo RTMS SMD (fixed) SMD (fixed) Study orsub-category N Mean (SD) Ν 95% CI 95% CI Mean (SD) Alonso 2001 10 -3.40(8.24) -0.25(3.92) -0.45 [-1.39, 0.50] 8 Total (95% CI) 10 -0.45 [-1.39, 0.50] Test for heterogeneity: not applicable Test for overall effect: Z = 0.93 (P = 0.35) Favours active RTMS Favours placebo RTMS Review: OCD: other medical Comparison: 02 Repetitive transcranial magnetic stimulation; active vs placebo 04 HAM-D: change score Active RTMS Placebo RTMS SMD (fixed) SMD (fixed) Study or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI Alonso 2001 10 -0.30(3.95) 0.25(1.16) -0.17 [-1.10, 0.76] Total (95% CI) -0.17 [-1.10, 0.76] 10 Test for heterogeneity: not applicable Test for overall effect: Z = 0.36 (P = 0.72) Favours active RTMS Favours placebo RTMS OCD: other medical Review: Comparison: 03 Repetitive transcranial magnetic stimulation; right vs left Outcome: 01 Y-BOCS @ post-treatment SMD (fixed) SMD (fixed) Right Left or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Right prefrontal v Left prefrontal 17.00(4.86) 6 16.67(12.31) 0.03 [-1.10, 1.16] Subtotal (95% CI) 0.03 [-1.10, 1.16] Test for heterogeneity: not applicable Test for overall effect: Z = 0.06 (P = 0.96) -2 Favours right Favours left OCD: other medical Review: Comparison: 03 Repetitive transcranial magnetic stimulation: right vs left 02 BDI @ post-treatment SMD (fixed) Study Right Left SMD (fixed) Mean (SD) Mean (SD) 95% CI 95% CI or sub-category 01 Right prefrontal v Left prefrontal 0.48 [-0.67, 1.64] Sachdev 2001 14.17(8.91) 6 9.67(8.26) Subtotal (95% CI) 0.48 [-0.67, 1.64] Test for heterogeneity: not applicable Test for overall effect: Z = 0.82 (P = 0.41) Favours right Favours left Review: OCD: other medical Comparison 03 Repetitive transcranial magnetic stimulation; right vs left 03 MADRS @ post-treatment Outcome: Study Right Left SMD (fixed) SMD (fixed) or sub-category N Mean (SD) Ν Mean (SD) 95% CL 95% CI 01 Right prefrontal v Left prefrontal Sachdev 2001 15.33(10.35) 6.00(7.51) 0.95 [-0.27, 2.18] Subtotal (95% CI) 0.95 [-0.27, 2.18] Test for heterogeneity: not applicable Test for overall effect: Z = 1.53 (P = 0.13) Favours right Favours left OCD: other medical Review: Comparison: 03 Repetitive transcranial magnetic stimulation; right vs left Outcome: 04 STAI-S @ post-treatment SMD (fixed) SMD (fixed) Study Right Left N Mean (SD) Ν Mean (SD) 95% CI or sub-category 01 Right prefrontal v Left prefrontal Sachdev 2001 6 0.04 [-1.10. 1.17] 6 45.50(9.67) 45.00(15.02) Subtotal (95% CI) 0.04 [-1.10, 1.17] Test for heterogeneity: not applicable Test for overall effect: Z = 0.06 (P = 0.95)

Favours right Favours left

Review: OCD: other medical Comparison: 03 Repetitive transcranial magnetic stimulation; right vs left Outcome: 05 Y-BOCS @ 1-month follow-up SMD (fixed) SMD (fixed) Study Right Left orsub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Right prefrontal v Left prefrontal Sachdev 2001 12.00(3.94) 6 16.50(8.31) -0.64 [-1.81, 0.54] Subtotal (95% CI) -0.64 [-1.81, 0.54] Test for heterogeneity: not applicable Test for overall effect: Z = 1.07 (P = 0.29) Favours right Favours left OCD: other medical Review: Comparison: 03 Repetitive transcranial magnetic stimulation; right vs left Outcome: 06 BDI @ 1-month follow-up SMD (fixed) SMD (fixed) Study Right Left Mean (SD) Ν Mean (SD) 95% CI 95% CI or sub-category Ν 01 Right prefrontal v Left prefrontal Sachdev 2001 11.60(14.64) 6 10.83(7.78) 0.06 [-1.07, 1.19] Subtotal (95% CI) 0.06 [-1.07, 1.19] Test for heterogeneity: not applicable Test for overall effect: Z = 0.10 (P = 0.92) Favours right Favours left Review: OCD: other medical Comparison: 03 Repetitive transcranial magnetic stimulation; right vs left 07 MADRS @ 1-month follow-up Outcome: SMD (fixed) SMD (fixed) Right Left or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Right prefrontal v Left prefrontal 12.20(8.81) 6.83(5.71) 0.67 [-0.51, 1.85] Subtotal (95% CI) 0.67 [-0.51, 1.85] Test for heterogeneity: not applicable Test for overall effect: Z = 1.11 (P = 0.27) -2 Favours right Favours left Review: OCD: other medical 03 Repetitive transcranial magnetic stimulation: right vs left Comparison: Outcome: 08 STAI-S @ 1-month follow-up SMD (fixed) SMD (fixed) Study Right Left or sub-category Mean (SD) Mean (SD) 95% CI 95% CI 01 Right prefrontal v Left prefrontal -0.05 [-1.18, 1.08] Sachdev 2001 44.50(18.96) 6 45.33(12.72) Subtotal (95% CI) -0.05 [-1.18, 1.08] Test for heterogeneity: not applicable Test for overall effect: Z = 0.08 (P = 0.93) Favours right Favours left Review: OCD: other medical Comparison: 03 Repetitive transcranial magnetic stimulation: right vs left 09 Non-responders (Y-BOCS 40%) @ 1-month follow-up Outcome: Right RR (fixed) RR (fixed) Study Left or sub-category nNn/N 95% CI 95% CI 01 Right prefrontal v Left prefrontal 1.00 [0.20, 4.95] 1.00 [0.20, 4.95] Sachdev 2001 2/6 2/6 Subtotal (95% CI) Total events: 2 (Right), 2 (Left) Test for heterogeneity: not applicable Test for overall effect: Z = 0.00 (P = 1.00)

0.2

0.5

Favours right Favours left

5

Review: OCD: other medical

Comparison: 04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment)

Outcome: 01 Adverse effects

Study or sub-category	Treatment 1 n/N	Treatment 2 n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Plasma exchange vs placeb	0			
Perlmutter 1999	7/10	2/10		3.50 [0.95, 12.90]
Subtotal (95% CI)	10	10	-	3.50 [0.95, 12.90]
Fotal events: 7 (Treatment 1), 2	? (Treatment 2)		-	•
Fest for heterogeneity: not appl	licable			
「est for overall effect: Z = 1.88				
02 IV immunoglobulin vs placeb	0			
Perlmutter 1999	6/10	2/10	 	3.00 [0.79, 11.44]
Subtotal (95% CI)	10	10		3.00 [0.79, 11.44]
Fotal events: 6 (Treatment 1), 2	? (Treatment 2)			•
Fest for heterogeneity: not appl				
Test for overall effect: $Z = 1.61$	(P = 0.11)			
03 Plasma exchange vs IV imm	unoglobulin			
Perlmutter 1999	7/10	6/10	-	1.17 [0.61, 2.23]
Subtotal (95% CI)	10	10	-	1.17 [0.61, 2.23]
Fotal events: 7 (Treatment 1), 6	(Treatment 2)		Γ	
Fest for heterogeneity: not appl				
Test for overall effect: Z = 0.47				
		0.01	0.1 1 10	100
		Favo	urs Treatment 1 Favours Treatme	nt 2

Review: OCD: other medical

Comparison: 04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment)

Outcome: 02 Leaving study early

Study or sub-category	Treatment 1 n/N	Treatment 2 n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Plasma exchange vs placebo)			
Perlmutter 1999	0/10	0/10		Not estimable
Subtotal (95% CI)	0	0		Not estimable
Total events: 0 (Treatment 1), 0	(Treatment 2)			
Test for heterogeneity: not applie	cable			
Test for overall effect: not applic	cable			
02 IV immunoglobulin vs placebo)			
Perlmutter 1999	1/10	0/10		— 3.00 [0.14, 65.90]
Subtotal (95% CI)	10	10		3.00 [0.14, 65.90]
Total events: 1 (Treatment 1), 0	(Treatment 2)		- -	
Test for heterogeneity: not appli	cable			
Test for overall effect: $Z = 0.70$	(P = 0.49)			
03 Plasma exchange vs IV immu	ınoglobulin			
Perlmutter 1999	0/10	1/10		0.33 [0.02, 7.32]
Subtotal (95% CI)	10	10		0.33 [0.02, 7.32]
Total events: 0 (Treatment 1), 1	(Treatment 2)		_	
Test for heterogeneity: not applie	cable			
Test for overall effect: $Z = 0.70$	(P = 0.49)			
		0.01	0.1 1 10	100
		Fav	ours Treatment 1 Favours Trea	itment 2

Review:

04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment) 03 Y-BOCS* Comparison:

Outcome:

Study or sub-category N	N	Treatment 1 Mean (SD)	N	Treatment 2 Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Plasma exchange vs placebo						
Perlmutter 1999	5	18.20(6.10)	7	29.71(3.55)		-2.24 [-3.83, -0.66]
Subtotal (95% CI)	5		7			-2.24 [-3.83, -0.66]
est for heterogeneity; not applicable	,					
est for overall effect: $Z = 2.77$ (P = 0	0.006)					
02 IV immunoglobulin vs placebo						
Perlmutter 1999	6	17.83(9.68)	7	29.71(3.55)		-1.57 [-2.88, -0.26]
ubtotal (95% CI)	6		7		-	-1.57 [-2.88, -0.26]
est for heterogeneity: not applicable						
est for overall effect: $Z = 2.35$ (P = 0	0.02)					
3 Plasma exchange vs IV immunoglo	bulin					
Perlmutter 1999	5	18.20(6.10)	6	17.83(9.68)	 _	0.04 [-1.15, 1.23]
Subtotal (95% CI)	5		6		-	0.04 [-1.15, 1.23]
est for heterogeneity: not applicable	,				Т	
est for overall effect: $Z = 0.07$ (P = 0	0.95)					
					-4 -2 0 2	4

Favours Treatment 1 Favours Treatment 2

Review:

OCD: other medical
04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment)
04 NIMH-Global Severity* Comparison:

Outcome:

Study or sub-category	N	Treatment 1 Mean (SD)	N	Treatment 2 Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
	ebo					
Perlmutter 1999	5	6.33(2.30)	7	8.29(0.76)		-1.15 [-2.43, 0.13]
Subtotal (95% CI)	5		7		-	-1.15 [-2.43, 0.13]
Fest for heterogeneity: not a	pplicable					
Test for overall effect: $Z = 1$.	77 (P = 0.08)					
02 IV immunoglobulin vs plac	ebo					
Perlmutter 1999	6	6.33(1.97)	7	8.29(0.76)		-1.26 [-2.50, -0.03]
Subtotal (95% CI)	6		7			-1.26 [-2.50, -0.03]
est for heterogeneity; not a	pplicable				_	
est for overall effect: $Z = 2$.	00 (P = 0.04)					
3 Plasma exchange vs IV im	munoglobulin					
Perlmutter 1999	5	6.33(2.30)	6	6.33(1.97)	 _	0.00 [-1.19, 1.19]
Subtotal (95% CI)	5		6			0.00 [-1.19, 1.19]
est for heterogeneity; not a	pplicable					
est for overall effect: Z = 0.	•					

Favours Treatment 1 Favours Treatment 2

Favours Treatment 1 Favours Treatment 2

Review:

04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment) 05 CGI-Symptom Severity* Comparison:

Outcome:

Study or sub-category	N	Treatment 1 Mean (SD)	N	Treatment 2 Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Plasma exchange vs place	ebo					
Perlmutter 1999	5	3.60(1.14)	7	4.86(0.48)		-1.43 [-2.78, -0.09]
Subtotal (95% CI)	5		7			-1.43 [-2.78, -0.09]
Test for heterogeneity: not ap	plicable					
Fest for overall effect: $Z = 2.0$	09 (P = 0.04)					
02 IV immunoglobulin vs place	ebo					
Perlmutter 1999	6	3.92(1.11)	7	4.86(0.48)		-1.06 [-2.25, 0.14]
Subtotal (95% CI)	6		7		-	-1.06 [-2.25, 0.14]
Fest for heterogeneity: not ap	plicable				-	
est for overall effect: $Z = 1$.	73 (P = 0.08)					
03 Plasma exchange vs IV im	munoglobulin					
Perlmutter 1999	5	3.60(1.14)	6	3.92(1.11)		-0.26 [-1.45, 0.93]
Subtotal (95% CI)	5		6			-0.26 [-1.45, 0.93]
Test for heterogeneity: not ap	plicable				7	
Test for overall effect: Z = 0.						

Review:

04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment) Comparison:

Outcome: 06 Global Assessment Scale*

Study or sub-category	N	Treatment 1 Mean (SD)	N	Treatment 2 Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl	
01 Plasma exchange vs placebo							
Perlmutter 1999	5	-63.40(12.36)	7	-54.86(4.30)		-0.93 [-2.16, 0.31]	
Subtotal (95% CI)	5		7			-0.93 [-2.16, 0.31]	
Test for heterogeneity: not applicab	le					,	
Test for overall effect: Z = 1.47 (P =	= 0.14)						
02 IV immunoglobulin vs placebo							
Perlmutter 1999	6	-62.83(10.69)	7	-54.86(4.30)		-0.94 [-2.11, 0.23]	
Subtotal (95% CI)	6		7			-0.94 [-2.11, 0.23]	
Test for heterogeneity: not applicab	ile				-		
Test for overall effect: $Z = 1.57$ (P =	= 0.12)						
03 Plasma exchange vs IV immuno	alobulin						
Perlmutter 1999	5	-63.40(12.36)	6	-62.83(10.69)	 _	-0.05 [-1.23, 1.14]	
Subtotal (95% CI)	5		6			-0.05 [-1.23, 1.14]	
Test for heterogeneity: not applicab	ile				T	,	
Test for overall effect: Z = 0.08 (P =							
					-4 -2 0 2	4	

Favours Treatment 1 Favours Treatment 2

Review:

OCD: other medical
04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment) Comparison:

Outcome:

Study or sub-category	N	Treatment 1 Mean (SD)	N	Treatment 2 Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl	
D1 Plasma exchange vs placeb	0						
Perlmutter 1999	5	4.20(2.28)	7	7.00(1.41)		-1.43 [-2.77, -0.09]	
ubtotal (95% CI)	5		7			-1.43 [-2.77, -0.09]	
est for heterogeneity: not appl	icable					•	
est for overall effect: Z = 2.09	(P = 0.04)						
02 IV immunoglobulin vs placeb	0						
Perlmutter 1999	6	5.33(1.37)	7	7.00(1.41)		-1.12 [-2.32, 0.09]	
ubtotal (95% CI)	6		7			-1.12 [-2.32, 0.09]	
est for heterogeneity: not appl	icable						
est for overall effect: $Z = 1.81$	(P = 0.07)						
3 Plasma exchange vs IV imm	unoglobulin						
Perlmutter 1999	5	4.20(2.28)	6	5.33(1.37)		-0.56 [-1.79, 0.66]	
ubtotal (95% CI)	5		6			-0.56 [-1.79, 0.66]	
est for heterogeneity; not appl	icable						
est for overall effect: Z = 0.90	(P = 0.37)						

Favours Treatment 1 Favours Treatment 2

Favours Treatment 1 Favours Treatment 2

Review: OCD: other medical 04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment) 08 NIMH-Depression*


Comparison: Outcome:

Study or sub-category	•		Treatment 2 N Mean (SD)		SMD (fixed) 95% CI	SMD (fixed) 95% Cl	
01 Plasma exchange vs plac	ebo						
Perlmutter 1999	5	3.60(2.19)	7	7.57(2.30)		-1.62 [-3.02, -0.23]	
ubtotal (95% CI)	5		7			-1.62 [-3.02, -0.23]	
est for heterogeneity; not a	pplicable						
est for overall effect: Z = 2							
)2 IV immunoglobulin vs plac	ebo						
Perlmutter 1999	6	4.83(2.14)	7	7.57(2.30)		-1.14 [-2.35, 0.07]	
Subtotal (95% CI)	6		7			-1.14 [-2.35, 0.07]	
est for heterogeneity; not a	pplicable				-		
est for overall effect: Z = 1	.85 (P = 0.06)						
)3 Plasma exchange vs IV ir	nmunoglobulin						
Perlmutter 1999	5	3.62(0.19)	6	4.83(2.14)		-0.69 [-1.93, 0.55]	
Subtotal (95% CI)	5		6			-0.69 [-1.93, 0.55]	
est for heterogeneity; not a	pplicable					,	
est for overall effect: Z = 1							

Review: OCD: other medical

Comparison: 04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment)

Outcome: 09 NIMH-OC*



Review: OCD: other medical

Comparison: 05 Plasma exchange vs IV immunoglobulin (child/adolescent: at 1 year after start of treatment)

Outcome: 01 Leaving study early

Study or sub-category	Plasma exchange n/N	IV immunoglobulin n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
Perlmutter 1999	2/10	0/9		4.55 [0.25, 83.70]
Total (95% CI) Total events: 2 (Plasma exch Test for heterogeneity: not a Test for overall effect: Z = 1	• •	9	-	4.55 [0.25, 83.70]
		0.01	01 1 10 1	÷ 00

Favours plasma exch. Favours IV immu.

Review: OCD: other medical

Comparison: 05 Plasma exchange vs IV immunoglobulin (child/adolescent: at 1 year after start of treatment)

Outcome: 02 Y-BOCS*


Study or sub-category	N F	Plasma exchange Mean (SD)	N IV	' immunoglobulin Mean (SD)			(fixed) i% Cl		SMD (fixed) 95% CI
Perlmutter 1999	5	10.50(8.27)	6	12.00(2.45)		-	_		-0.24 [-1.43, 0.96]
Total (95% CI) Test for heterogeneity: not Test for overall effect: Z =			6						-0.24 [-1.43, 0.96]
					-4	-2	Ö	2	4

Favours plasma exch. Favours IV immu.

Review: OCD: other medical

Comparison: 05 Plasma exchange vs IV immunoglobulin (child/adolescent: at 1 year after start of treatment)

Outcome: 03 Global Assessment Scale*



Favours plasma exch. Favours IV immu.